Astellas Pharma Inc. (ALPMF)
- Previous Close
9.84 - Open
9.60 - Bid --
- Ask --
- Day's Range
9.84 - 9.84 - 52 Week Range
9.13 - 17.00 - Volume
53 - Avg. Volume
2,295 - Market Cap (intraday)
17.647B - Beta (5Y Monthly) --
- PE Ratio (TTM)
492.07 - EPS (TTM)
0.02 - Earnings Date --
- Forward Dividend & Yield 0.46 (4.70%)
- Ex-Dividend Date Mar 28, 2024
- 1y Target Est
--
Astellas Pharma Inc. manufactures, markets, and imports and exports pharmaceuticals in Japan and internationally. The company provides XTANDI, a treatment for prostate cancer; XOSPATA, a treatment for patients who have relapsed or refractory acute myeloid leukemia with a FLT3 mutation; and PADCEV, a treatment for patients with metastatic urothelial cancer. It also offers Evrenzo, a treatment for anemia associated with chronic kidney disease; Betanis/Myrabetriq/BETMIGA, a treatment for overactive bladder; and Prograf and Advagraf/Graceptor/ASTAGRAF XL immunosuppressants. Th company has a research collaboration with Vivtex Corporation to evaluate Vivtex's GI-ORIS screening and formulation platform technology to support the development of novel and oral versions of a therapeutic candidate provided by Astellas; and a partnership agreement with Roche Diabetes Care Japan Co., Ltd. to develop and commercialize integrated diabetes self-management solution. The company was founded in 1923 and is headquartered in Tokyo, Japan.
www.astellas.com--
Full Time Employees
March 31
Fiscal Year Ends
Sector
Industry
Recent News: ALPMF
Performance Overview: ALPMF
Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: ALPMF
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: ALPMF
Valuation Measures
Market Cap
16.80B
Enterprise Value
20.57B
Trailing P/E
574.74
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
1.78
Price/Book (mrq)
1.82
Enterprise Value/Revenue
0.01
Enterprise Value/EBITDA
0.12
Financial Highlights
Profitability and Income Statement
Profit Margin
1.06%
Return on Assets (ttm)
0.39%
Return on Equity (ttm)
1.10%
Revenue (ttm)
1.6T
Net Income Avi to Common (ttm)
17.05B
Diluted EPS (ttm)
0.02
Balance Sheet and Cash Flow
Total Cash (mrq)
364.47B
Total Debt/Equity (mrq)
57.78%
Levered Free Cash Flow (ttm)
89.71B
Research Analysis: ALPMF
Company Insights: ALPMF
ALPMF does not have Company Insights